SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corcept Therapeutics Incorporated (CORT)
CORT 73.50+1.7%Oct 31 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw1/7/2006 6:03:00 AM
  Read Replies (1) of 32
 
waiting to hear:

1Q06: Corlux phase II results in
Alzheimer?s disease (80 patients

1H06: Corlux phase III results from
U.S.-based 07 trial for PMD

1H06: Corlux results from a proof of
concept study in mitigating weight
gain associated with the use of
Zyprexa (LLY)

2H06: Corlux phase III results from
U.S.-based 06 trial and Europeanbased
09 trial for PMD

thinking of adding this to the real portfolio, but trying to find the right price. seems like a bit of leverage hear.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News